Log doses, track injection sites, and visualize drug levels
In the first quarter of 2025, 29% of commercially insured patients initiated their diabetes treatment with a GLP-1
(FDA approvals of Wegovy for cardiovascular disease and Zepbound for sleep apnea occurred in 2024 and therefore these uses are likely not reflected in Part D data through 2024.) More than half of gross spending in 2024 was on semaglutide products (Ozempic, 47%
GLP-1RAs also show potential in addressing bulimia nervosa, a disorder characterized by impaired satiety signaling and heightened sensitivity to food rewards
The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis
This technique is called overshoot-and-adjust, and it consistently delivers more accurate doses than trying to draw precisely to the mark on the first pull